ストックスクリーナーアプリを入手
48.26
1.83%
-0.90
前日終値:
$49.16
開ける：
$48.5
24時間の取引高:
12.46M
Relative Volume:
0.81
時価総額：
$163.61B
収益：
$46.69B
当期純損益:
$15.29B
株価収益率:
14.06
EPS:
3.4329
ネットキャッシュフロー:
$9.25B
1週間 パフォーマンス:
+5.65%
1か月 パフォーマンス:
-14.83%
6か月 パフォーマンス:
-25.07%
1年 パフォーマンス:
-54.18%
1日の値動き範囲:
$48.03
$48.91
1週間の範囲:
$45.57
$50.43
52週間の値動き範囲:
$45.05
$112.52
Novo Nordisk Adr Stock (NVO) Company Profile
NVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.26 | 218.44B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | 再開されました | Jefferies | Underperform |
| 2025-10-01 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-09-29 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-09-16 | アップグレード | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | アップグレード | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-31 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-07-30 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-04-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | アップグレード | Kepler | Hold → Buy |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2025-01-06 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Neutral |
| 2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 開始されました | Argus | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | ダウングレード | UBS | Neutral → Sell |
| 2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
| 2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-01-25 | ダウングレード | Liberum | Hold → Sell |
| 2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-05-11 | ダウングレード | UBS | Buy → Neutral |
| 2020-05-04 | 開始されました | Cowen | Market Perform |
| 2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
| 2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
Why Is Everyone Talking About Novo Nordisk Stock? - Finviz
Trump's MAGA backlash and the GOP's scramble for an Obamacare fix: Morning Rundown - NBC News
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs - GlobeNewswire Inc.
Why Novo Nordisk Stock Is Sinking This Week - Finviz
Even With Pricing and Competitive Pressure, Novo Nordisk's Portfolio Warrants a Wide Moat - Morningstar
Novo Nordisk ADR earnings missed by $0.09, revenue fell short of estimates - Investing.com Australia
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts - Sahm
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx - Sahm
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock rebound after recent weaknessRecession Risk & Real-Time Volume Triggers - Fundação Cultural do Pará
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal - Sahm
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates - Investing.com South Africa
Will Novo Nordisk A s (b Shares) Adrhedged stock gain from strong economyExit Point & Trade Opportunity Analysis - fcp.pa.gov.br
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs - Sahm
Wegovy maker Novo Nordisk cuts guidance again but Medicare pricing deal uplifts investors - The Globe and Mail
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates By Investing.com - Investing.com Nigeria
$NVO Last opportunity! for NYSE:NVO by alexei_erchov - TradingView
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It - Sahm
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House - Sahm
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb - Sahm
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Sahm
Bengals-Bears game today: Chicago Bears outlast Cincinnati Bengals for wild 47-42 win on Williams' TD pass to Loveland - ABC7 Chicago
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Sahm
Will Novo Nordisk A s (b Shares) Adrhedged stock deliver strong dividend growthExit Point & Smart Investment Allocation Tips - fcp.pa.gov.br
Can Novo Nordisk A s (b Shares) Adrhedged stock outperform in 2025 bull marketJuly 2025 Chart Watch & Fast Momentum Entry Tips - fcp.pa.gov.br
P/E Ratio Insights for Novo Nordisk - Sahm
Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk - Sahm
Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail
Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.22%
大文字化:
|
ボリューム (24 時間):